Safety and Efficacy of Tegileridine in Painless Gastrointestinal Endoscopy
This single-center, randomized, double-blind, active-controlled clinical trial aims to evaluate the safety and efficacy of tegileridine, a biased μ-opioid receptor agonist, in patients undergoing gastrointestinal endoscopy under sedation, compared with sufentanil. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation were enrolled and randomly assigned in a 1:1 ratio to receive either tegileridine or sufentanil. The primary outcome is the incidence of respiratory depression. Secondary outcomes include the incidences of hypotension and postoperative nausea and vomiting, sedation success rate, supplemental propofol dose, procedure duration, recovery time, and patient satisfaction. This study will provide clinical evidence to support individualized and precision-based anesthesia strategies for gastrointestinal endoscopy.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Background: Gastrointestinal endoscopy under sedation is a cornerstone of the diagnosis and treatment of digestive diseases, reducing patient discomfort and improving adherence. Conventional anesthesia with sufentanil and propofol is associated with significant adverse effects, including respiratory depression, gastrointestinal adverse reactions, postoperative nausea and vomiting (PONV), and hemodynamic fluctuations. Tegileridine mediates analgesia through preferential activation of G protein signaling at the μ-opioid receptor while reducing β-arrestin pathway activation, thereby lowering the risks of gastrointestinal adverse reactions and respiratory depression. To date, no clinical studies have investigated tegileridine for gastrointestinal endoscopy under sedation, and pharmacokinetic data and dose-adjustment guidelines for older adults remain unavailable.
Objectives: To systematically compare the safety and efficacy of tegileridine and sufentanil for gastrointestinal endoscopy under sedation, establish the suitability of tegileridine in this setting, and determine an appropriate dose for older patients, thereby supporting the development of individualized and precision-based anesthesia strategies.
Study Design: This is a single-center, randomized, double-blind, active-controlled trial. A total of 338 patients scheduled for gastrointestinal endoscopy under sedation will be enrolled and randomly assigned in a 1:1 ratio to the tegileridine group or the sufentanil group. Participants, staff involved in administering sedation, and outcome assessors will be blinded to treatment allocation. Only the nurses responsible for preparing the study medications will be unblinded.
Study Population: Eligible patients will be aged 18-75 years, have a body mass index (BMI) of 18.0-28.0 kg/m², a Mallampati airway classification of I or II, and an American Society of Anesthesiologists (ASA) physical status classification of I or II, have no contraindications to routine gastroscopy, and provide written informed consent. Exclusion criteria include severe cardiopulmonary disease, hepatic or renal failure, a history of opioid allergy, chronic opioid dependence, hypokalemia, a history of QT interval prolongation, pregnancy, and breastfeeding. Patients whose gastroscopy lasts longer than 30 minutes or who experience adverse events that cannot be resolved with treatment will be withdrawn from the study.
Interventions: Patients in the tegileridine group will receive intravenous tegileridine at 0.01 mg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. Patients in the sufentanil group will receive intravenous sufentanil at 0.1 μg/kg, followed 3 minutes later by intravenous propofol at 1.5 mg/kg. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental propofol at 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes.
Outcome Measures: The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. Secondary outcomes include safety measures (hypotension, PONV, the need for airway interventions, and changes in vital signs at multiple time points), efficacy measures (sedation success rate, the number of supplemental propofol doses and total propofol dose, procedure duration, and recovery time), and patient satisfaction, assessed on a scale of 1-10.
Expected Results: Compared with the sufentanil group, the tegileridine group is expected to have a lower incidence of respiratory depression, a lower risk of PONV, and more stable vital signs while achieving adequate analgesia for gastrointestinal endoscopy under sedation. Tegileridine may therefore offer a safer anesthesia option for older patients and patients with obesity.
Type d'étude
Type d'étude
Inscription (Estimé)
Inscription
Phase
Phase
- Phase 4
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Fang Peng Gao, MS
- Numéro de téléphone: 17760577442
- E-mail: gao1664@163.com
Lieux d'étude
-
-
Hainan
-
Haikou, Hainan, Chine, 570311
- Recrutement
- The Second Affiliated Hospital of Hainan Medical University
-
Contact:
- Fang Peng Gao, MS
- Numéro de téléphone: 17760577442
- E-mail: gao1664@163.com
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Patients aged 18-75 years scheduled for gastrointestinal endoscopy under sedation.
- Body mass index (BMI) of 18.0-28.0 kg/m².
- Mallampati airway classification of I or II.
- American Society of Anesthesiologists (ASA) physical status classification of I or II.
- No contraindications to routine gastroscopy.
- Written informed consent signed by the patient and their family member.
Exclusion Criteria:
- Severe cardiopulmonary disease.
- Hepatic or renal failure.
- History of opioid allergy.
- Chronic opioid dependence.
- Hypokalemia or a history of QT interval prolongation.
- Pregnancy or breastfeeding.
Withdrawal Criteria:
- Gastroscopy duration exceeding 30 minutes.
- Adverse events that cannot be resolved with treatment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Tegileridine Group
Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg. |
Tegileridine 0.01 mg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. |
|
Comparateur actif: Sufentanil Group
Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg. |
Tegileridine 0.01 mg/kg or sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. Sufentanil 0.1 μg/kg will be administered intravenously, followed 3 minutes later by intravenous propofol 1.5 mg/kg to induce sedation. The procedure will begin once the eyelash reflex is absent and the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) score is ≤3. If signs of inadequate anesthesia occur during the examination, such as body movement, coughing, or a heart rate >100 beats/min, supplemental intravenous propofol 0.5-1.0 mg/kg will be administered at intervals of at least 2 minutes. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Respiratory Depression
Délai: Periprocedural, up to 2 hours
|
The primary outcome is the incidence of respiratory depression, defined as a respiratory rate <8 breaths/min or peripheral oxygen saturation (SpO₂) <90%. |
Periprocedural, up to 2 hours
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Incidence of Hypotension
Délai: Periprocedural, up to2 hours
|
Hypotension is defined as a decrease in systolic blood pressure (SBP) of more than 20% from baseline. The incidence of hypotension will be assessed during the periprocedural observation period and reported as the percentage of participants experiencing at least one episode of hypotension. |
Periprocedural, up to2 hours
|
|
Incidence of Postoperative Nausea and Vomiting (PONV)
Délai: Periprocedural, up to 24 hours after the endoscopic procedure
|
The incidence of postoperative nausea and vomiting (PONV) will be assessed within 24 hours after completion of the endoscopic procedure. PONV is defined as the occurrence of at least one episode of nausea, vomiting, or both during the observation period. The outcome will be reported as the percentage of participants experiencing PONV. |
Periprocedural, up to 24 hours after the endoscopic procedure
|
|
Heart Rate
Délai: Periprocedural, up to 2hours
|
Heart rate (beats/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2hours
|
|
Mean Arterial Pressure
Délai: Periprocedural, up to 2 hours
|
Mean arterial pressure (MAP, mmHg) will be recorded at the following six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2 hours
|
|
Respiratory Rate
Délai: Periprocedural, up to 2 hours
|
Respiratory rate (breaths/min) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2 hours
|
|
Peripheral Oxygen Saturation
Délai: Periprocedural, up to 2 hours
|
Peripheral oxygen saturation (SpO₂, %) will be recorded at six prespecified time points: before entering the procedure room, after anesthesia induction, at endoscope insertion, 2 minutes after endoscope insertion, at endoscope withdrawal, and upon leaving the procedure room. |
Periprocedural, up to 2 hours
|
|
Percentage of Participants With Successful Sedation Based on Body Movement at Endoscope Insertion and Rescue Sedative Use
Délai: Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
|
Percentage of participants who meet both criteria for successful sedation: no body movement at endoscope insertion and no use of any rescue sedative other than the study drug during the endoscopic procedure. |
Periprocedural, at endoscope insertion for body movement and throughout the endoscopic procedure for rescue sedative use. Sedation success is determined at procedure completion.
|
|
Number of Supplemental Propofol Doses and Total Propofol Dose
Délai: Periprocedural, up to 2 hours
|
The number of supplemental propofol doses administered during the endoscopic procedure will be recorded for each participant. The total propofol dose (mg), including the initial dose and all supplemental doses, will also be calculated. Both outcomes will be assessed at the completion of the endoscopic procedure. |
Periprocedural, up to 2 hours
|
|
Procedure Duration
Délai: During the endoscopic procedure
|
Procedure duration is defined as the time interval from endoscope insertion to endoscope withdrawal, measured in minutes. |
During the endoscopic procedure
|
|
Recovery Time
Délai: Periprocedural,up to 2 hours
|
Recovery time is defined as the time interval from endoscope withdrawal to the time when the participant first meets the predefined discharge criteria for the post-anesthesia care unit (PACU), measured in minutes. |
Periprocedural,up to 2 hours
|
|
Patient Satisfaction
Délai: Post-procedure assessment.
|
Post-procedure assessment.
|
|
|
Sedation Success Rate
Délai: At the end of the procedure.
|
At the end of the procedure.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Estimé)
Achèvement primaire
Achèvement de l'étude (Estimé)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2026-K68-01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .